tiprankstipranks
Eisai submits MAA for lecanemab to EMA
The Fly

Eisai submits MAA for lecanemab to EMA

Eisai (ESALY) and Biogen (BIIB) announced that Eisai has submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer’s disease to the European Medicines Agency. This application is based on the results of the Phase III Clarity AD study and the Phase IIb clinical study, which demonstrated that lecanemab treatment showed a reduction of clinical decline in early AD and is subject to a validation to determine whether the EMA accepts the application for review.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on BIIB:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles